Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats

Nephrology Dialysis Transplantation

Volumn 25, Issue 9, 2010, Pages 2889-2898

  Nagasu, Hajime ^a   Satoh, Minoru ^a   Kuwabara, Atsunori ^a   Yorimitsu, Daisuke ^a   Sakuta, Takeo ^a   Tomita, Naruya ^a   Kashihara, Naoki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

chronic kidney disease; NAD(P)H oxidase; rac1; reactive oxygen species; sympathetic nerve

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DAHL SALT SENSITIVE RAT; ENZYME ACTIVITY; GLOMERULUS; HISTOPATHOLOGY; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; BLOTTING, WESTERN; CATECHOLAMINES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEART RATE; KIDNEY; MALE; NADPH OXIDASE; NEUROPEPTIDE Y; OXIDATION-REDUCTION; RATS; RATS, INBRED DAHL; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY;

EID: 77956252045     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq139     Document Type: Article

References (41)

1. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315
2. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745
3. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850
4. Hall JE, Jones DW, Kuo JJ et al. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003; 5: 386-392
5. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706
6. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576
7. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19: 1354-1357
8. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with endstage renal disease. Circulation 2002; 105: 1354-1359
9. Salomonsson M, Brannstrom K, Arendshorst WJ. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol Renal Physiol 2000; 278: F138-F147
10. Denton KM, Shweta A, Anderson WP. Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 2002; 13: 27-34
11. Wang D, Jose P,Wilcox CS. Beta(1) receptors protect the renal afferent arteriole of angiotensin-infused rabbits from norepinephrine-induced oxidative stress. J Am Soc Nephrol 2006; 17: 3347-3354
12. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236
13. Fujimoto S, Satoh M, Horike H et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008; 31: 305-313
14. Satoh M, Fujimoto S, Arakawa S et al. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 3806-3813
15. Namikoshi T, Tomita N, Satoh M et al. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Am J Hypertens 2007; 20: 1085-1091
16. Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep 2008; 10: 233-240
17. Muhlbauer B, Spohr F, Schmidt R, Osswald H. Role of renal nerves and endogenous dopamine in amino acid-induced glomerular hyperfiltration. Am J Physiol 1997; 273: F144-F149
18. DiBona GF, Sawin LL. Renal nerves in renal adaptation to dietary sodium restriction. Am J Physiol 1983; 245: F322-F328
19. Namikoshi T, Tomita N, Fujimoto S et al. Isohumulones derived from hops ameliorate renal injury via an anti-oxidative effect in Dahl saltsensitive rats. Hypertens Res 2007; 30: 175-184
20. Koya D, Hayashi K, Kitada M et al. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003; 14: S250-S253
21. Satoh M, Ogita H, Takeshita K et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006; 103: 7432-7437
22. Satoh M, Fujimoto S, Haruna Y et al. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144-F1152
23. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61: 186-194
24. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006; 98: 453-462
25. Modlinger PS,Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24: 354-365
26. Veelken R, Vogel EM, Hilgers K et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19: 1371-1378
27. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004; 286: F606-F616
28. Schluter T, Grimm R, Steinbach A et al. Neonatal sympathectomy reduces NADPH oxidase activity and vascular resistance in spontaneously hypertensive rat kidneys. Am J Physiol Regul Integr Comp Physiol 2006; 291: R391-R399
29. Wojciak-Stothard B, Ridley AJ. Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. J Cell Biol 2003; 161: 429-439
30. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension 2003; 41: 621-624
31. Hocherl K, Kammerl M, Kees F et al. Role of renal nerves in stimulation of renin, COX-2, and nNOS in rat renal cortex during salt deficiency. Am J Physiol Renal Physiol 2002; 282: F478-F484
32. DiBona GF, Sawin LL. Effect of renal denervation on dynamic autoregulation of renal blood flow. Am J Physiol Renal Physiol 2004; 286: F1209-F1218
33. Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19: 342-347
34. Faber JE, Szymeczek CL, Salvi SS, Zhang H. Enhanced alpha1-adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats. AmJ Physiol Heart Circ Physiol 2006; 291:H2272-H2281
35. Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res 2004; 94: 37-45
36. Oelze M, Daiber A, Brandes RP et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-684
37. Boivin V, Jahns R, Gambaryan S et al. Immunofluorescent imaging of beta 1-and beta 2-adrenergic receptors in rat kidney. Kidney Int 2001; 59: 515-531
38. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11: 1003-1011
39. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs 2006; 66: 477-496
40. Krespi PG, Makris TK, Hatzizacharias AN et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 463-467
41. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281